The impact of changing from ocrelizumab to ofatumumab on disease activity, infection and immunological parameters in patients with multiple sclerosis

被引：0
|
作者：
Montague, Turlough [1 ]
Chatterton, Sophie [1 ]
Cheung, Emily [1 ]
Thomas, Karen [1 ]
Simpson-Burke, Nicole [1 ]
Markoulis, Katherine [1 ]
Miller, Celia [1 ]
Fontes-Villalba, Ariadna [1 ]
Parratt, John [1 ]
机构：
[1] Royal North Shore Hosp, Sydney, NSW, Australia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1715/1624
引用
收藏
页码：1084 / 1084
页数：1
相关论文
共 50 条
  • [21] Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study
    Seery, Nabil
    Sharmin, Sifat
    Li, Vivien
    Nguyen, Ai-Lan
    Meaton, Claire
    Atvars, Roberts
    Taylor, Nicola
    Tunnell, Kelsey
    Carey, John
    Marriott, Mark P.
    Buzzard, Katherine A.
    Roos, Izanne
    Dwyer, Chris
    Baker, Josephine
    Taylor, Lisa
    Spriggs, Kymble
    Kilpatrick, Trevor J.
    Kalincik, Tomas
    Monif, Mastura
    CNS DRUGS, 2021, 35 (08) : 907 - 918
  • [22] Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study
    Nabil Seery
    Sifat Sharmin
    Vivien Li
    Ai-Lan Nguyen
    Claire Meaton
    Roberts Atvars
    Nicola Taylor
    Kelsey Tunnell
    John Carey
    Mark P. Marriott
    Katherine A. Buzzard
    Izanne Roos
    Chris Dwyer
    Josephine Baker
    Lisa Taylor
    Kymble Spriggs
    Trevor J. Kilpatrick
    Tomas Kalincik
    Mastura Monif
    CNS Drugs, 2021, 35 : 907 - 918
  • [23] Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study
    Seery, N.
    Sharmin, S.
    Li, V.
    Nguyen, A.
    Meaton, C.
    Atvars, R.
    Taylor, N.
    Tunnell, K.
    Carey, J.
    Marriott, M. P.
    Buzzard, K. A.
    Roos, I.
    Dwyer, C.
    Baker, J.
    Taylor, L.
    Spriggs, K.
    Kilpatrick, T. J.
    Kalincik, T.
    Monif, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (4_SUPPL) : 32 - 33
  • [24] Ocrelizumab for Post-Alemtuzumab Paradoxical Disease Activity in Highly Active Multiple Sclerosis
    Adamec, Ivan
    Habek, Mario
    CLINICAL NEUROPHARMACOLOGY, 2022, 45 (05) : 139 - 141
  • [25] Ofatumumab Reduces Disability Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis
    Montalban, Xavier
    Cohen, Jeffrey A.
    Comi, Giancarlo
    Coyle, Patricia K.
    Kappos, Ludwig
    Li, Bingbing
    Sfikas, Nikolaos
    Willi, Roman
    Haring, Dieter A.
    Merschhemke, Martin
    Hauser, Stephen L.
    NEUROLOGY, 2020, 94 (15)
  • [26] Ofatumumab Reduces Disability Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis
    Kappos, Ludwig
    Montalban, Xavier
    Coyle, Patricia
    Nicholas, Jacqueline
    Meuth, Sven
    Li, Bingbing
    Ramanathan, Krishnan
    Su, Wendy
    Willi, Roman
    Haering, Dieter A.
    Hauser, Stephen
    NEUROLOGY, 2021, 96 (15)
  • [27] Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis
    Kappos, L.
    Wolinsky, J. S.
    Giovannoni, G.
    Arnold, D. L.
    Lublin, F.
    Wang, Q.
    Model, F.
    Wei, W.
    Garren, H.
    Manfrini, M.
    Belachew, S.
    Hauser, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 309 - 310
  • [28] IMMUNOLOGICAL INVITRO PARAMETERS IN PATIENTS WITH MULTIPLE-SCLEROSIS AND IN NORMAL INDIVIDUALS
    PLATZ, P
    FOG, T
    MORLING, N
    SVEJGAARD, A
    SONDERSTRUP, G
    RYDER, LP
    THOMSEN, M
    JERSILD, C
    ACTA PATHOLOGICA ET MICROBIOLOGICA SCANDINAVICA SECTION C-IMMUNOLOGY, 1976, 84 (06): : 501 - 510
  • [29] Letter to the Editor: Remission of Graves' Disease After Initiation of Ocrelizumab in Patients with Multiple Sclerosis
    Casany-Fernandez, Rosa
    Gascon-Gimenez, Francisco
    Matarredona Solaz, Enrique Juan
    Pardo Lozano, Felipe
    Dominguez-Moran, Jose Andres
    Ferri Ciscar, Jordi
    Real Collado, Jose Tomas
    THYROID, 2023, 33 (02) : 267 - 269
  • [30] Switching from natalizumab to ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Van Lierop, Z.
    Toorop, A.
    Willemse, E.
    Strijbis, E.
    Kalkers, N.
    Moraal, B.
    Barkhof, F.
    Teunissen, C.
    Killestein, J.
    Van Kempen, Z.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 310 - 311
12345